Lyell Immunopharma Inc. (LYEL) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Lyell Immunopharma Inc. (NASDAQ: LYEL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $11.04 (-2.34% 1D, market cap $270.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LYEL ranks #797 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LYEL carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BIOA (BioAge Labs Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $269.4M) and RCKT (Rocket Pharmaceuticals Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $267.9M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).
Per LYEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001806952), Lyell Immunopharma Inc. generated $36.0K in revenue (-41.0% YoY), -$274.4M in net income, and -$150.8M in free cash flow against $340.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While LYEL currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.87) and Max Pain ($11.59) forces dealer call-delta covering toward $47.25.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Lyell Immunopharma Inc. (LYEL) dropped -2.34% to $11.04, trading at 10% of its 52-week range ($7.2 – $45). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Lyell Immunopharma Inc. (LYEL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Lyell Immunopharma Inc. (LYEL) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Lyell Immunopharma Inc. (LYEL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Lyell Immunopharma Inc. (LYEL) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Lyell Immunopharma Inc. (LYEL) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Lyell Immunopharma Inc. (LYEL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Lyell Immunopharma Inc. (LYEL) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Lyell Immunopharma Inc. (LYEL) market action, institutional positioning, and fundamental catalysts.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapi
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -41.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on LYEL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for LYEL. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Lyell Immunopharma Inc. (LYEL) ranks #797 by composite RQD confidence (30/100, grade E) and #528 by equity capitalization ($270.5M). Within this direct 5-issuer industry benchmark cohort, QTTB leads on earnings valuation at 8.9x trailing P/E, while QTTB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. QTTB currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with LYEL at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LYEL
ACTIVE
Lyell Immunopharma Inc. | E | 30/100 | — | — | -35.0% | -2.34% | $270.5M | Benchmark Subject |
| BIOA BioAge Labs Inc. | E | 31/100 | — | — | -35.0% | -1.18% | $269.4M | /bioa-vs-lyel → |
| RCKT Rocket Pharmaceuticals Inc. | E | 28/100 | — | — | -35.0% | -3.94% | $267.9M | /rckt-vs-lyel → |
| QTTB Q32 Bio Inc. | D+ | 53/100 | 8.9x | — | 85.0% | +0.45% | $265.2M | /qttb-vs-lyel → |
| FULC Fulcrum Therapeutics Inc. | E | 32/100 | — | — | -35.0% | -1.59% | $283.4M | /fulc-vs-lyel → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lyell Immunopharma Inc. (LYEL) reported GAAP revenue of $36.0K (-41.0% vs. FY2024 revenue of $61.0K , and -72.3% cumulative change since FY2023) , GAAP net income of -$274.4M, operating cash flow of -$150.0M, and free cash flow of -$150.8M (+7.4% YoY). On the balance sheet, LYEL closed FY2025 with $340.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $36.0K | -$274.4M | -$150.0M | -$150.8M | $340.1M | — |
| FY2024 (FY) | 2024-12-31 | $61.0K | -$343.0M | -$162.4M | -$162.9M | $490.9M | — |
| FY2023 (FY) | 2023-12-31 | $130.0K | -$234.6M | -$163.7M | -$163.7M | — | — |
As of 2026-11-03, Lyell Immunopharma Inc. (NASDAQ: LYEL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $11.04 (-2.34% 1D, market cap $270.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LYEL ranks #797 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LYEL carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BIOA (BioAge Labs Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $269.4M) and RCKT (Rocket Pharmaceuticals Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $267.9M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).
Per LYEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001806952), Lyell Immunopharma Inc. generated $36.0K in revenue (-41.0% YoY), -$274.4M in net income, and -$150.8M in free cash flow against $340.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
LYEL last traded at $11.04 (-2.34% on volume of 113,265 shares), positioning the stock +1.56% above its 50-day simple moving average ($10.87) and -34.09% below its 200-day simple moving average ($16.75). Across its 52-week range of $7.20 to $45.00, LYEL sits at the 10.2% percentile with a 14-day RSI of 60.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($9.66 to $12.42).
Why LYEL Stock dropped -2.34% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, LYEL carries an RQD Score of 30 and a letter grade of E, with the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The score is built from five pillars, each scored out of 20:
Taken together, the investor implication is that upside depends on events outside current cash generation, while the downside is supported by negative operating economics and weak forensic signals. The rating frames this as a stock to avoid on a risk-adjusted basis, not a valuation opportunity on current fundamentals.
Lyell Immunopharma Inc. (LYEL) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry, per the profile. The source data does not describe its products, customers, or revenue model. Reported revenue is near zero in each period shown in the SEC financials, so the source does not support a conclusion about how the company monetizes its activities. Not available in source data for further detail on products or customers.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-269.4M | $-274.4M | N/A | $-150.8M | $60.2M | N/A |
| FY 2024 | $0.1M | $-358.8M | $-343.0M | N/A | $-162.9M | $105.6M | N/A |
| FY 2023 | $0.1M | $-247.0M | $-234.6M | N/A | $-163.7M | N/A | N/A |
Per the SEC financials, the company reported operating and net losses in each period shown, with operating margin and net margin both reported at -60% in the market data, and gross margin at 0%. ROIC is reported at -35%, and FCF yield at 0%. Cash declined from $105.6M in FY 2024 to $60.2M in FY 2025. The Altman Z-Score of 2.5, Piotroski F-Score of 3 of 9, and Debt/Equity of 0.5 are reported per the Roarable RQD rating; the source does not provide the underlying debt figures to verify the ratio.
Per the recent news feed, the flagged items are:
The news feed carries no proprietary signals. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are present (see below).
Real-time company headlines, analyst actions, and sector developments for Lyell Immunopharma Inc. (LYEL) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Lyell Immunopharma Inc. (LYEL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Lyell Immunopharma Inc. (LYEL) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Lyell Immunopharma Inc. (LYEL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Lyell Immunopharma Inc. (LYEL) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Lyell Immunopharma Inc. (LYEL) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Lyell Immunopharma Inc. (LYEL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Lyell Immunopharma Inc. (LYEL) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Lyell Immunopharma Inc. (LYEL) market action, institutional positioning, and fundamental catalysts.
Welcome to the LYEL (Lyell Immunopharma Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on LYEL, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Lyell Immunopharma Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on LYEL, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $11.31 (52-wk range $7.20 - $45.00), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).